Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Synta Pharmaceuticals Corp.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologically confirmed metastatic (Stage IV) melanoma of cutaneous origin
ECOG performance status of \<=2
Measurable disease according to modified RECIST
Life expectancy of greater than 12 weeks
LDH \<= 2.0 x ULN
Clinical lab values within protocol parameters.
At least 18 years old and able and willing to provide informed consent to participate
You may not be if
Previous cytotoxic chemotherapy treatment for melanoma
Received more than one regimen of immunotherapy, kinase inhibitor, biologic therapy, vaccine or investigational non-chemotherapeutic treatment for melanoma.
Presence of brain metastases
Presence or history (\<= 5 years) of a second malignancy other than nonmelanoma skin cancer or cervical carcinoma in situ
Female subjects who are pregnant or nursing
Clareo Health | Elesclomol (STA-4783) With Paclitaxel Versus Paclitaxel Alone in Melanoma
